Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Paukenschlag in den USA - diese Aktien könnten profitieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QL3C | ISIN: US2300311063 | Ticker-Symbol:
NASDAQ
17.05.24
21:59 Uhr
23,160 US-Dollar
-0,650
-2,73 %
1-Jahres-Chart
CULLINAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CULLINAN THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CULLINAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCullinan Therapeutics files to sell 14.4M shares of common stock for holders1
DoCullinan Oncology reports Q1 results1
MiCullinan Therapeutics Inc reports results for the quarter ended in March - Earnings Summary-
MiCullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results173Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases...
► Artikel lesen
29.04.Cullinan Therapeutics appoints CFO1
29.04.Cullinan Therapeutics Appoints Fenton As CFO-
29.04.Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer139CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment...
► Artikel lesen
29.04.Cullinan Therapeutics, Inc. - 8-K, Current Report1
26.04.PEGY, CGEM and IFBD among mid-day movers7
24.04.Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?3
24.04.Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors ...2
16.04.Cullinan Therapeutics Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity1
16.04.Cullinan Oncology changes name, pivots to autoimmune disease4
16.04.Cullinan Oncology rebrands, halts lymphoma trial to reflect autoimmune refocus3
16.04.UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday245
16.04.Cullinan Oncology To Expand Into Autoimmune Diseases, Privately Places $280 Mln; Stock Up In Pre-Market1
16.04.Cullinan Therapeutics expands into autoimmune diseases1
16.04.Cullinan Therapeutics, Inc. - 8-K, Current Report1
16.04.Cullinan Therapeutics gets $280M via oversubscribed private placement2
16.04.Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases163CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep...
► Artikel lesen
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1